Schizophrenia

On this page

Quick Overview

Schizophrenia is a severe mental illness affecting ~1% of the population, characterized by positive symptoms (hallucinations, delusions), negative symptoms (apathy, social withdrawal), and cognitive impairment. NICE CG178 emphasizes early intervention in first-episode psychosis (FEP), systematic antipsychotic selection, and structured pathways for treatment-resistant schizophrenia (TRS). Timely recognition and evidence-based management significantly improve long-term outcomes.

Core Facts & Concepts

Diagnostic Criteria (ICD-10)

  • ≥1 month of symptoms with ≥1 of: thought echo/insertion/withdrawal/broadcasting, delusions of control, persistent delusions, persistent hallucinations (typically auditory)
  • Or ≥2 of: persistent hallucinations, thought disorder, catatonic behavior, negative symptoms

Figure 1: MRI brain scan showing enlarged lateral ventricles in schizophrenia patient

First-Episode Psychosis (FEP) Pathway

  • 🎯 NICE target: Assessment by Early Intervention in Psychosis (EIP) service within 2 weeks of referral
  • EIP services for ≥3 years or until age 65 (whichever longer)
  • Start antipsychotic at lowest licensed dose, titrate cautiously

Antipsychotic Choice Algorithm

  • Discuss benefits/risks of oral antipsychotics (first-generation vs second-generation)
  • Consider: metabolic (weight gain, diabetes), extrapyramidal (akathisia, parkinsonism), cardiovascular (QTc), prolactin effects
  • Avoid polypharmacy: Use monotherapy unless during cross-titration
  • Review response at 4-6 weeks; if inadequate, trial different antipsychotic (offer ≥2 agents)

Clozapine Initiation Criteria

  • 💊 TRS definition: Inadequate response to ≥2 antipsychotics (including ≥1 second-generation) each trialed for 6-8 weeks at therapeutic dose
  • Clozapine = gold standard for TRS (~30% of cases)
  • Requires weekly FBC for 18 weeks, then fortnightly to 52 weeks, then monthly (monitor neutropenia risk)

Figure 2: ECG showing prolonged QTc interval in patient on antipsychotic medication

Monitoring Requirements

ParameterBaselineWeek 12Annually
Weight/BMI
Lipids/glucose
BP/pulse
ProlactinIf symptomatic-If symptomatic
ECGIf risk factors-If on high-dose

Problem-Solving Approach

Managing Treatment Resistance

  1. Confirm diagnosis: Rule out substance misuse, organic causes, medication non-adherence
  2. Optimize current antipsychotic: Ensure adequate dose/duration (6-8 weeks therapeutic trial)
  3. Trial second antipsychotic: Different class if first trial failed
  4. Consider clozapine after 2 failed trials (don't delay-efficacy time-sensitive)
  5. Augmentation strategies if partial clozapine response: Add aripiprazole, amisulpride, or ECT

Acute Agitation/Violence

  • 🚩 De-escalation first: Verbal, environmental modification
  • Rapid tranquilization: IM lorazepam (1-2mg) OR IM haloperidol (5mg) + promethazine (50mg)
  • Monitor every 15 minutes post-IM (respiratory rate, BP, temperature, hydration)
  • Avoid combining IM antipsychotic + benzodiazepine unless essential

⚠️ Warning: Antipsychotic polypharmacy increases mortality risk-avoid except during cross-titration

Red Flags Requiring Urgent Action

  • 🚩 Neuroleptic malignant syndrome: Fever, rigidity, elevated CK, autonomic instability
  • 🚩 Clozapine neutropenia: Neutrophils <1.5×10⁹/L (stop immediately)
  • 🚩 QTc >500ms or >60ms increase from baseline
  • 🚩 Acute dystonia/oculogyric crisis (give IM procyclidine 5-10mg)

Analysis Framework

Differential Diagnosis of Psychosis

ConditionKey DiscriminatorsDuration
SchizophreniaNegative symptoms, functional decline>1 month
Brief psychotic disorderAcute stressor, full recovery<1 month
SchizoaffectiveMood episodes concurrent with psychosisVariable
Drug-inducedTemporal link to substance (cannabis, stimulants)Resolves with abstinence
DeliriumFluctuating consciousness, acute onsetDays-weeks
Bipolar (manic)Elevated mood, grandiosity predominate≥1 week

First-Generation vs Second-Generation Antipsychotics

FeatureFirst-Gen (e.g., haloperidol)Second-Gen (e.g., olanzapine)
Extrapyramidal effectsHigher riskLower risk
Metabolic effectsLower riskHigher risk (weight, diabetes)
Prolactin elevationMore commonVariable (risperidone high)
CostLowerHigher

Visual Aid

Clozapine Monitoring Schedule

TimeframeFBC FrequencyAction if Neutrophils <1.5
Weeks 1-18WeeklyStop clozapine, daily FBC
Weeks 19-52FortnightlyStop, refer hematology
After 52 weeksMonthlyStop, urgent specialist review

Key Points Summary

FEP pathway: EIP assessment within 2 weeks, start antipsychotic at lowest dose, provide ≥3 years specialized care

TRS criteria: Inadequate response to ≥2 antipsychotics (including ≥1 second-generation) each for 6-8 weeks at therapeutic dose-then offer clozapine

Clozapine monitoring: Weekly FBC for 18 weeks, fortnightly to 52 weeks, monthly thereafter; stop if neutrophils <1.5×10⁹/L

Avoid polypharmacy: Use antipsychotic monotherapy; combining agents increases mortality without clear benefit

Monitoring essentials: Weight/glucose/lipids at baseline, 12 weeks, and annually; ECG if cardiovascular risk factors or high-dose therapy

Rapid tranquilization: De-escalate first; if needed, use IM lorazepam OR haloperidol + promethazine; monitor every 15 minutes post-administration

Common pitfall: Declaring treatment resistance before ensuring adequate dose/duration and ruling out non-adherence or substance misuse

Practice Questions: Schizophrenia

Test your understanding with these related questions

A 58-year-old man presents with progressive memory loss and behavioral changes over 10 months. MRI shows asymmetric frontotemporal atrophy. What is the most appropriate symptomatic treatment?

1 of 5

Flashcards: Schizophrenia

1/10

_____ is associate with a poorer prognosis in Schizophrenia

Hint: Onset

TAP TO REVEAL ANSWER

_____ is associate with a poorer prognosis in Schizophrenia

Gradual

browseSpaceflip

Enjoying this lesson?

Get full access to all lessons, practice questions, and more.

Start Your Free Trial